The aim of this study was to investigate in vitro activities of fidaxomicin and other antibiotics against 188 Clostridium difficile strains collected from different centers of Hungary. C. difficile isolates showed minimum inhibitory concentration (MIC) range for fidaxomicin of </=0.008-0.5 mg/L, with a MIC90 of 0.125 mg/L. Only four isolates (2.1%) had 0.5 mg/L MIC to fidaxomicin. The obtained MICs showed identical distribution to those found in the EUCAST database for wild-type strains
This study analysed 330 Clostridium difficile strains isolated from patients with C. difficile infec...
We determined the in vitro activity of SMT19969 and 11 comparators, including metronidazole, vancomy...
The microflora-sparing properties of fidaxomicin were examined during the conduct of a randomized cl...
Fidaxomicin is bactericidal against Clostridium difficile. The combined results of 8 in vitro studie...
Background: Clostridium difficile infection (CDI) is a significant cause of morbidity and mortality ...
Our study showed the antibiotic susceptibility profile of toxigenic Clostridium difficile isolated f...
OBJECTIVES: In November 2008, a study was performed with support from the European Centre for Diseas...
A total of 403 nonduplicate isolates of Clostridium difficile were collected at three major teaching...
In 2011 a surveillance study for the susceptibility to fidaxomicin and epidemiology of Clostridium d...
The effects of the inoculum, pH, cation concentrations, and different lots of commercial media on th...
Fidaxomicin (FDX) is a novel antimicrobial agent with narrow-spectrum and potent bactericidal activi...
International audienceOBJECTIVES: Although exposure to antibiotics can cause Clostridium difficile i...
Effects on growth and toxin A production of sub-MIC concentrations of six different antibiotics were...
rhoea, demonstrates narrow-spectrum bactericidal activity via inhibition of RNA polymerase. In this ...
Objectives: SMT19969 is a novel antimicrobial under clinical development for the treatment of Clostr...
This study analysed 330 Clostridium difficile strains isolated from patients with C. difficile infec...
We determined the in vitro activity of SMT19969 and 11 comparators, including metronidazole, vancomy...
The microflora-sparing properties of fidaxomicin were examined during the conduct of a randomized cl...
Fidaxomicin is bactericidal against Clostridium difficile. The combined results of 8 in vitro studie...
Background: Clostridium difficile infection (CDI) is a significant cause of morbidity and mortality ...
Our study showed the antibiotic susceptibility profile of toxigenic Clostridium difficile isolated f...
OBJECTIVES: In November 2008, a study was performed with support from the European Centre for Diseas...
A total of 403 nonduplicate isolates of Clostridium difficile were collected at three major teaching...
In 2011 a surveillance study for the susceptibility to fidaxomicin and epidemiology of Clostridium d...
The effects of the inoculum, pH, cation concentrations, and different lots of commercial media on th...
Fidaxomicin (FDX) is a novel antimicrobial agent with narrow-spectrum and potent bactericidal activi...
International audienceOBJECTIVES: Although exposure to antibiotics can cause Clostridium difficile i...
Effects on growth and toxin A production of sub-MIC concentrations of six different antibiotics were...
rhoea, demonstrates narrow-spectrum bactericidal activity via inhibition of RNA polymerase. In this ...
Objectives: SMT19969 is a novel antimicrobial under clinical development for the treatment of Clostr...
This study analysed 330 Clostridium difficile strains isolated from patients with C. difficile infec...
We determined the in vitro activity of SMT19969 and 11 comparators, including metronidazole, vancomy...
The microflora-sparing properties of fidaxomicin were examined during the conduct of a randomized cl...